Omeros (OMER)
(Delayed Data from NSDQ)
$3.64 USD
-0.32 (-8.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $3.65 +0.01 (0.27%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 81 - 100 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
OMS721 IgA Nephropathy Clinical Plan Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Record OMIDRIA Sales Achieved in 4Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Cambridge Collaboration Inked; Looking Ahead to Potential Regulatory Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Senior Convertible Note Financing Removes CRG Overhang; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q3 Financials; Near-Term Financing Risk Remains
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Another Orphan Drug Designation for OMS721; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Data Misinterpretation Creates Attractive Entry Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
Mixed Results for Corticosteroid-Free IgAN Cohort at 12 Weeks
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Another OMS721 Orphan Drug Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
2Q18 Financial Results Reported; OMIDRIA Reimbursement Reinstatement Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
2Q18 Earnings Preview; Staying Focused on OMIDRIA Reuptake and OMS721; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Final OMIDRIA Patent Litigation Concluded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Receives European Orphan Drug Designation Positive Opinion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
OMS527 Commences Clinical Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D